Clinical Trial Update: Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing a combined antiinflammatory and antiangiogenic therapy in patients with hormone-refractory prostate cancer; the study status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-10-06